Article
YBX1 mediates translation of oncogenic transcripts to control cell competition in AML.
Leukemia - 1 Feb 2022
Perner Florian, Schnoeder Tina M, Xiong Yijun, Jayavelu Ashok Kumar, Mashamba Nomusa, Santamaria Nuria Tubio, Huber Nicolas, Todorova Kristina, Hatton Charles, Perner Birgit, Eifert Theresa, Murphy Ciara, Hartmann Maximilian, Hoell Jessica I, Schröder Nicolas, Brandt Sabine, Hochhaus Andreas, Mertens Peter R, Mann Matthias, Armstrong Scott A, Mandinova Anna, Heidel Florian H
Abstract excerpt
Persistence of malignant clones is a major determinant of adverse outcome in patients with hematologic malignancies. Despite the fact that the majority of patients with acute myeloid leukemia (AML) achieve complete remission after chemotherapy, a large proportion of them relapse as a result of residual malignant cells. These persistent clones have a competitive advantage and can re-establish disease. Therefore,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
